Pancreatic cancer

Score 8 = 7.4 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 4 of 5 trials are Phase 2+.

• Ph2NCT06050317 · Shandong Cancer Hospital and Institute · Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
• Ph2NCT07173387 · Shandong Cancer Hospital and Institute · Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
• Ph2NCT07683221 · Shandong Cancer Hospital and Institute · SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
• Ph1NCT07173374 · Shandong Cancer Hospital and Institute · Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
• Ph1/Ph2NCT06844422 · Shandong Cancer Hospital and Institute · Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

Score 6.2 = 5.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0.5 posters. 2 of 2 trials are Phase 2+.

• ESMO 2026 3150P (poster) · A phase Ib/II study of HRS-4642 plus nimotuzumab in patients with KRAS G12D-mutant advanced pancreatic ductal adenocarcinoma

• Ph1/Ph2NCT07802184 · West China Hospital · GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
• Ph1/Ph2NCT07175389 · West China Hospital · JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

Score 4.5 = 4.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph2NCT05908747 · Tianjin Medical University Cancer Institute and Hospital · Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
• Ph2/Ph3NCT06361888 · Hutchmed · A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
• Ph3NCT07436741 · Tianjin Medical University Cancer Institute and Hospital · Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Score 3.3 = 3.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05908747 · Tianjin Medical University Cancer Institute and Hospital · Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
• Ph3NCT07436741 · Tianjin Medical University Cancer Institute and Hospital · Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Score 3.3 = 3 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT05911217 · CARsgen Therapeutics Co., Ltd. · A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
• Ph3NCT07138846 · Lepu Biopharma Co., Ltd. · A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05969860 · Mayo Clinic · At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
• Ph2NCT07285044 · Mayo Clinic · The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07619521 · National Cancer Institute (NCI) · Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07748611 · Northwestern University · SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07765836 · Massachusetts General Hospital · Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06202066 · Roswell Park Cancer Institute · Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07905131 · Daniel Nussbaum, M.D. · A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07895498 · Memorial Sloan Kettering Cancer Center · A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07871461 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07802418 · Herlev Hospital · Molecularly Tailored Therapy in Advanced Pancreatic Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07824960 · University of Virginia · Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07705919 · Ohio State University Comprehensive Cancer Center · DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07594626 · Northwestern University · BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06941857 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
• Ph2NCT05014776 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07705074 · Martin Huellner · FAPI PET Imaging - An Exploratory Study

Score 2.7 = 2.4 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT05685602 · National Cancer Institute (NCI) · CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
• Ph1/Ph2NCT06904378 · Washington University School of Medicine · ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07282912 · Yale University · Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07377526 · M.D. Anderson Cancer Center · TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07539155 · University of Arkansas · Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

Score 2.6 = 1.9 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph3NCT07081360 · Minia University · Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
• Ph1NCT07132541 · Minia University · Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07478523 · University Hospital, Bordeaux · FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07354919 · HealthPartners Institute · Axelopran for Advanced Cancer in Patients Receiving Opioids

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06790602 · University of California, San Diego · Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT06998940 · SWOG Cancer Research Network · Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07529483 · Ohio State University Comprehensive Cancer Center · Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07344220 · Hoag Memorial Hospital Presbyterian · Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07561463 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sacituzumab Tirumotecan for Pancreatic Cancer

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07283705 · M.D. Anderson Cancer Center · A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07440290 · Cancer Research UK · DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07214298 · Roswell Park Cancer Institute · Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07432633 · Blue Earth Diagnostics · [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07716228 · Second Affiliated Hospital, Zhejiang University, School of Medicine · Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07226856 · Mayo Clinic · BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07586813 · Peking University People's Hospital · Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

Score 2.1 = 1.9 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT05034627 · OHSU Knight Cancer Institute · Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
• Ph2NCT06630325 · OHSU Knight Cancer Institute · A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06503146 · National Cancer Institute (NCI) · 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection